Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;23(6):421-444.
doi: 10.1038/s41573-024-00943-2. Epub 2024 May 13.

Frameworks for transformational breakthroughs in RNA-based medicines

John R Androsavich  1   2
Affiliations
Review

Frameworks for transformational breakthroughs in RNA-based medicines

John R Androsavich. Nat Rev Drug Discov. 2024 Jun.

Abstract

RNA has sparked a revolution in modern medicine, with the potential to transform the way we treat diseases. Recent regulatory approvals, hundreds of new clinical trials, the emergence of CRISPR gene editing, and the effectiveness of mRNA vaccines in dramatic response to the COVID-19 pandemic have converged to create tremendous momentum and expectation. However, challenges with this relatively new class of drugs persist and require specialized knowledge and expertise to overcome. This Review explores shared strategies for developing RNA drug platforms, including layering technologies, addressing common biases and identifying gaps in understanding. It discusses the potential of RNA-based therapeutics to transform medicine, as well as the challenges associated with improving applicability, efficacy and safety profiles. Insights gained from RNA modalities such as antisense oligonucleotides (ASOs) and small interfering RNAs are used to identify important next steps for mRNA and gene editing technologies.

PubMed Disclaimer

References

    1. Curreri, A., Sankholkar, D., Mitragotri, S. & Zhao, Z. RNA therapeutics in the clinic. Bioeng. Transl. Med. 8, e10374 (2023). - PubMed - DOI
    1. Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020). - PubMed - DOI
    1. Xie, W., Chen, B. & Wong, J. Evolution of the market for mRNA technology. Nat. Rev. Drug Discov. 20, 735–736 (2021). - PubMed - DOI
    1. Hogan, M. J. & Pardi, N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu. Rev. Med. 73, 17–39 (2022). - PubMed - DOI
    1. Warne, N. et al. Delivering 3 billion doses of Comirnaty in 2021. Nat. Biotechnol. 41, 183–188 (2023). This article provides first-hand account of the technical and operational feats required to deliver large-scale production of a COVID-19 mRNA vaccine during the pandemic. - PubMed

LinkOut - more resources